{"doi":"10.2215/cjn.03790417","title":"A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders","abstract":"<jats:sec>\n            <jats:title>Background and objectives</jats:title>\n            <jats:p>Post-transplant lymphoproliferative disorders arising after kidney transplantation portend an increased risk of morbidity and mortality. Retransplantation of patients who had developed post-transplant lymphoproliferative disorder remains questionable owing to the potential risks of recurrence when immunosuppression is reintroduced. Here, we investigated the feasibility of kidney retransplantation after the development of post-transplant lymphoproliferative disorder.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Design, setting, participants, &amp; measurements</jats:title>\n            <jats:p>We reviewed the data from all patients who underwent kidney retransplantation after post-transplant lymphoproliferative disorder in all adult kidney transplantation centers in France between 1998 and 2015.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Results</jats:title>\n            <jats:p>We identified a total of 52 patients with kidney transplants who underwent 55 retransplantations after post-transplant lymphoproliferative disorder. The delay from post-transplant lymphoproliferative disorder to retransplantation was 100±44 months (28–224); 98% of patients were Epstein–Barr virus seropositive at the time of retransplantation. Induction therapy for retransplantation was used in 48 patients (<jats:italic toggle=\"yes\">i.e.</jats:italic>, 17 [31%] patients received thymoglobulin, and 31 [57%] patients received IL-2 receptor antagonists). Six patients were also treated with rituximab, and 53% of the patients received an antiviral drug. The association of calcineurin inhibitors, mycophenolate mofetil, and steroids was the most common maintenance immunosuppression regimen. Nine patients were switched from a calcineurin inhibitor to a mammalian target of rapamycin inhibitor. One patient developed post-transplant lymphoproliferative disorder recurrence at 24 months after retransplantation, whereas post-transplant lymphoproliferative disorder did not recur in 51 patients.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions</jats:title>\n            <jats:p>The recurrence of post-transplant lymphoproliferative disorder among patients who underwent retransplantation in France is a rare event.</jats:p>\n          </jats:sec>","journal":"Clinical Journal of the American Society of Nephrology","year":2017,"id":18174,"datarank":1.7440378858001224,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"self_citation_contribution":0.5456379239589579,"citation_network_contribution":1.1983999618411645,"self_endowment_contribution":0.5456379239589579,"citer_contribution":1.1983999618411645,"corpus_percentile":null,"corpus_rank":null,"citation_count":37,"citer_count":34,"citers_with_citation_signal":27,"citers_with_endowment":27,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":127314,"name":"Etienne Cellot","orcid":null,"position":1,"is_corresponding":false},{"id":127315,"name":"Jacques Dantal","orcid":null,"position":2,"is_corresponding":false},{"id":127316,"name":"Olivier Thaunat","orcid":null,"position":3,"is_corresponding":false},{"id":127317,"name":"François Provot","orcid":null,"position":4,"is_corresponding":false},{"id":127318,"name":"Bénédicte Janbon","orcid":null,"position":5,"is_corresponding":false},{"id":127319,"name":"Matthias Buchler","orcid":null,"position":6,"is_corresponding":false},{"id":127320,"name":"Dany Anglicheau","orcid":null,"position":7,"is_corresponding":false},{"id":127321,"name":"Pierre Merville","orcid":null,"position":8,"is_corresponding":false},{"id":127322,"name":"Philippe Lang","orcid":null,"position":9,"is_corresponding":false},{"id":126742,"name":"Luc Frimat","orcid":null,"position":10,"is_corresponding":false},{"id":127323,"name":"Charlotte Colosio","orcid":null,"position":11,"is_corresponding":false},{"id":127324,"name":"Eric Alamartine","orcid":null,"position":12,"is_corresponding":false},{"id":126780,"name":"Nassim Kamar","orcid":"0000-0003-1930-8964","position":13,"is_corresponding":false},{"id":127325,"name":"Anne Elisabeth Heng","orcid":null,"position":14,"is_corresponding":false},{"id":127326,"name":"Antoine Durrbach","orcid":"0000-0003-0385-8726","position":15,"is_corresponding":false},{"id":127327,"name":"Valérie Moal","orcid":null,"position":16,"is_corresponding":false},{"id":127328,"name":"Joseph Rivalan","orcid":null,"position":17,"is_corresponding":false},{"id":127329,"name":"Isabelle Etienne","orcid":null,"position":18,"is_corresponding":false},{"id":127330,"name":"Marie Noelle Peraldi","orcid":null,"position":19,"is_corresponding":false},{"id":127331,"name":"Anne Moreau","orcid":null,"position":20,"is_corresponding":false},{"id":2646,"name":"Bruno Moulin","orcid":"0000-0001-6772-7165","position":21,"is_corresponding":false},{"id":127313,"name":"Sophie Caillard","orcid":"0000-0002-0525-4291","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28818847","pmcid":"PMC5628715","openalex_id":"https://openalex.org/W2747457204","authors":[],"funders":[],"total_grants":0,"fwci":1.9942,"citation_percentile":0.88445502,"influential_citations":3,"citation_trend":[{"year":2017,"count":2},{"year":2018,"count":3},{"year":2019,"count":3},{"year":2020,"count":9},{"year":2021,"count":9},{"year":2022,"count":3},{"year":2023,"count":2},{"year":2024,"count":4},{"year":2025,"count":1}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://cjasn.asnjournals.org/content/clinjasn/12/10/1663.full.pdf","host_type":"journal"},{"url":"https://cjasn.asnjournals.org/content/clinjasn/12/10/1663.full.pdf","host_type":"BRONZE"},{"url":"https://cjasn.asnjournals.org/content/clinjasn/12/10/1663.full.pdf","host_type":"publisher"},{"url":"https://journals.lww.com/01277230-201710000-00015","host_type":"publisher"},{"url":"https://doi.org/10.2215/cjn.03790417","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28818847","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5628715","host_type":"repository"}],"fields_of_study":["Viral-associated cancers and disorders","Renal Transplantation Outcomes and Treatments","Cytomegalovirus and herpesvirus research","Medicine","Adult","Aged","Drug Substitution","Drug Therapy, Combination","Feasibility Studies","Female","France","Graft Survival","Humans","Immunosuppressive Agents","Kidney Transplantation","Lymphoproliferative Disorders","Male","Middle Aged","Recurrence","Registries","Reoperation","Retrospective Studies","Risk Factors","Time Factors","Treatment Outcome","Young Adult"],"mesh_terms":["Adult","Aged","Drug Therapy, Combination","Feasibility Studies","Female","France","Graft Survival","Humans","Immunosuppressive Agents","Lymphoproliferative Disorders","Male","Middle Aged","Recurrence","Registries","Reoperation","Retrospective Studies","Risk Factors","Time Factors","Kidney Transplantation","Treatment Outcome","Young Adult","Drug Substitution"],"keywords":["Medicine","Post-transplant lymphoproliferative disorder","Immunosuppression","Lymphoproliferative disorders","Rituximab","Calcineurin","Thymoglobulin","Internal medicine","Transplantation","Kidney transplantation","Gastroenterology","Surgery","Lymphoma","Kidney","Adult","Herpesvirus 4, human","Cohort studies","Reoperation","Receptors, interleukin-2","France","Neoplasm Recurrence, Local","Antiviral Agents","Mycophenolic acid","Humans","Calcineurin Inhibitors","Epstein-barr Virus Infections","Antilymphocyte Serum"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-03T19:00:53.451372Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}